Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 7 of 7 results for tralokinumab

  1. Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis (TA814)

    Evidence-based recommendations on abrocitinib (Cibinqo), tralokinumab (Adtralza) or upadacitinib (Rinvoq) for treating moderate to severe atopic dermatitis.

    Technology appraisal guidance
    Published
    3 August 2022
    View recommendations

    Sections for TA814

  2. Lebrikizumab for treating moderate to severe atopic dermatitis in people 12 years and over (TA986)

    Evidence-based recommendations on lebrikizumab (Ebglyss) for treating moderate to severe atopic dermatitis in people 12 years and over.

    Technology appraisal guidance
    Published
    10 July 2024
    View recommendations

    Sections for TA986

  3. Nemolizumab for treating moderate to severe atopic dermatitis in people 12 years and over ID6221

    In development [GID-TA11183] Expected publication date: 16 July 2025

    Technology appraisal guidance
    In development

  4. Tralokinumab for treating moderate to severe atopic dermatitis [ID3734]

    Discontinued [GID-TA10596]

    Technology appraisal guidance
    Discontinued

  5. Upadacitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3733]

    Discontinued [GID-TA10597]

    Technology appraisal guidance
    Discontinued

  6. Abrocitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3768]

    Discontinued [GID-TA10764]

    Technology appraisal guidance
    Discontinued

  7. Tralokinumab for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3823]

    Discontinued [GID-TA10702]

    Technology appraisal guidance
    Discontinued